Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emergent BioSolutions, a biopharmaceutical company that manufactures, develops and commercialises vaccines and antibody therapies that assist the body's immune system to prevent or treat disease, has reported a revenue of $73.99m for the third quarter ended 30 September 2010, compared to $43.27m for the same period in 2009.
Subscribe to our email newsletter
Emergent posted a net income of $13.12m for the third quarter 2010, or $0.41 per diluted share, compared to net loss of $3.95m, or $0.03 per diluted share, for the comparable period in 2009.
Emergent’s income from operations was $20.61m, compared to $949,000 for the comparable period in 2009.
For the nine months ended 30 September 2010, Emergent posted revenues of $182.92m, compared to $180.98m for the year ago period.
The company’s net income for the nine months ended 30 September 2010 was $25.45m,or $0.8 per diluted share, compared to $26.91m, or $0.86 per diluted share, for the comparable period in 2009.
Emergent has reported income from operations of $38.59m for the nine months ended 30 September 2010, compared to $36.03m for the year ago period.
Emergent chief financial officer R Don Elsey said that with the financial performance for the third quarter and first nine months of 2010 they remain on track to end the year within the range of revenue and net income guidance.
"We continue to experience high production yields related to BioThrax manufacturing out of Building 12 and we expect to deliver significant quantities of the anthrax vaccine into the SNS during the fourth quarter of 2010," Elsey said.
"In addition, we are pleased that we closed on the Trubion Pharmaceuticals acquisition and are already integrating the Seattle operations."